Summit Therapeutics Inc. (SMMT): who owns it and who trades it
As of Nov 16, 2026, SMMT insiders reported 4 purchases worth $52.2M in the last 12 months. The largest buyer was Mahkam Zanganeh (CEO), with $50M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Summit Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SMMT
241 funds and institutions reported SMMT shares worth $2B at the end of Q2 2026, about 18% of the company. The largest holder is Baker Bros. Advisors LP with 4.2%.
Funds and institutions (13F) 18%Everyone else 82%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 32.79M | 4.22% | $478M | -10% |
| FMR LLC (Fidelity) | 10.04M | 1.29% | $146M | -7% |
| State Street Corp | 9.54M | 1.23% | $139M | +36% |
| BlackRock, Inc. | 9.53M | 1.23% | $139M | -1% |
| Vanguard Capital Management LLC | 5.73M | 0.74% | $83.6M | +0% |
| UBS Group AG | 5.23M | 0.67% | $76.3M | +42% |
| Vanguard Portfolio Management LLC | 5.04M | 0.65% | $73.5M | -4% |
| Goldman Sachs Group Inc | 4.51M | 0.58% | $65.8M | +1353% |
| T. Rowe Price Associates | 3.89M | 0.50% | $56.7M | -53% |
| Point72 Asset Management, L.P. | 3.70M | 0.48% | $53.9M | +372% |
| Geode Capital Management, LLC | 3.43M | 0.44% | $50M | +3% |
| Millennium Management LLC | 2.35M | 0.30% | $34.2M | +1760% |
| Adage Capital Partners Gp, L.l.c. | 1.99M | 0.26% | $29M | – |
| Balyasny Asset Management L.P. | 1.90M | 0.25% | $27.7M | +247% |
| Citadel Advisors LLC | 1.73M | 0.22% | $25.1M | +291% |
| Aberdeen Group plc | 1.69M | 0.22% | $24.7M | +155% |
| Squarepoint Ops LLC | 1.59M | 0.20% | $23.2M | +159% |
| Morgan Stanley | 1.45M | 0.19% | $21.1M | -12% |
| Norges Bank | 1.38M | 0.18% | $20.1M | – |
| Logos Global Management LP | 1.35M | 0.17% | $19.7M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SMMT insiders reported $52.2M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Mahkam Zanganeh | CEO | Purchase | 3.81M | $13.12 | $50M | Form 4 |
| Jun 4, 2026 | Robert W Duggan | CEO | Purchase | 100,000 | $14.60 | $1.5M | Form 4 |
| Jun 4, 2026 | Manmeet Singh Soni | CFO | Purchase | 25,000 | $14.43 | $361K | Form 4 |
| Jun 4, 2026 | Manmeet Singh Soni | CFO | Purchase | 25,000 | $14.46 | $362K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mahkam Zanganeh | Co-Chief Executive Officer, Director, 10% owner | $50M | – | Jun 12, 2026 |
| Robert W Duggan | Co-Chief Executive Officer, Director, 10% owner | $1.5M | – | Jun 4, 2026 |
| Manmeet Singh Soni | COO and CFO, Director | $722K | – | Jun 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SMMT short interest
Moderate short interest. 5.3% of SMMT shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 42%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 42.26M SMMT shares were sold short, 5.3% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 4.50M shares, buying them all back would take about 9.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 42.26M | 5.28% | +3% | 4.50M | 9.4 |
| Oct 15, 2026 | 40.90M | 5.13% | -1% | 5.82M | 7.0 |
| Sep 30, 2026 | 41.16M | 5.16% | +0% | 8.50M | 4.8 |
| Sep 15, 2026 | 41.08M | 5.15% | -1% | 6.26M | 6.6 |
| Aug 31, 2026 | 41.33M | 5.18% | +10% | 6.24M | 6.6 |
| Aug 14, 2026 | 37.43M | 4.69% | +3% | 4.31M | 8.7 |
| Jul 31, 2026 | 36.25M | 4.54% | -3% | 4.09M | 8.9 |
| Jul 15, 2026 | 37.33M | 4.81% | -6% | 3.39M | 11.0 |
| Jun 30, 2026 | 39.86M | 5.13% | +8% | 5.96M | 6.7 |
| Jun 15, 2026 | 36.81M | 4.74% | +2% | 8.25M | 4.5 |
| May 29, 2026 | 36.13M | 4.65% | +21% | 4.41M | 8.2 |
| May 15, 2026 | 29.82M | 3.84% | +2% | 4.73M | 6.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Summit Therapeutics company events
Summit Therapeutics filed 19 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026AnnouncementSummit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission. Filing
- Nov 4, 2026ResultsReleased financial results. Filing
- Sep 29, 2026AgreementSummit Therapeutics Inc. entered into a securities purchase agreement with AstraZeneca Holdings B.V., a subsidiary of AstraZeneca plc, for the issuance and sale by the Company of 108,955.3686 shares of the Company’s newly designated Class A Convertible Preferred Stock, par value $0.01 per share, at… Filing
- Sep 15, 2026AnnouncementSummit Therapeutics Inc. issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented today at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer. Filing
- Sep 14, 2026AnnouncementSummit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced that updated data, including overall survival, from the randomized, double-blind Phase III HARMONi-2 trial, is being presented at the International Association for the Study of Lung Cancer’s 2026 World… Filing
- Sep 3, 2026AnnouncementSummit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced positive overall survival results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or… Filing
- Aug 26, 2026AnnouncementSummit Therapeutics Inc. issued a press release noting that its partner, Akeso, Inc., announced positive topline results from the randomized Phase III HARMONi-GI1 study evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with… Filing
- Aug 5, 2026AnnouncementSummit Therapeutics Inc. issued a press release announcing the expansion of its global registration-enabling clinical development program for ivonescimab into urothelial carcinoma, or bladder cancer, with the planned initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Filing
- Jul 23, 2026AgreementSummit Therapeutics Inc. entered into a distribution agreement with J.P. Morgan Securities LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering… Filing
- Jul 23, 2026ResultsReleased financial results. Filing
- Jul 22, 2026AnnouncementSummit Therapeutics Inc. issued a press release announcing results of an updated overall survival analysis from the Phase III HARMONi clinical trial. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 11, 2026AnnouncementShared information with investors. Filing
- Jun 3, 2026AnnouncementThe Audit Committee and all independent directors of the Board of Directors of Summit Therapeutics Inc. approved one or more Company affiliates to purchase shares of the Company’s common stock under the previously disclosed at-the-market offering with JP Morgan Securities LLC acting as Sales Agent. Filing
- Jun 1, 2026AnnouncementSummit Therapeutics Inc. issued a press release announcing new results from the AK112-206 trial, a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer co-sponsored by the Company and its partner, Akeso, Inc., featuring ivonescimab. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Jan 29, 2026AnnouncementSummit Therapeutics Inc. issued a press release announcing that the U.S. Food & Drug Administration has accepted for filing the Company's Biologics License Application seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor-mutated locally… Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Summit Therapeutics financials
Famous investors that hold SMMT
3 of the 50 well-known investors we track reported holding SMMT in their latest 13F filing. The largest position is Ken Griffin's, worth $64M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 3.78M | $64M | 0.0% | +119% |
| Israel Englander · Millennium Management | Q3 2026 | 230,974 | $3.9M | 0.0% | -90% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 35,926 | $608K | 0.0% | -99% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Summit Therapeutics Inc. (SMMT) stock
Who owns the most SMMT stock?
The largest reported owner of Summit Therapeutics Inc. (SMMT) is Baker Bros. Advisors LP, with 4.2% of the company. In total, 241 funds and institutions reported holding SMMT at the end of Q2 2026, together about 18% of the shares. See the largest owners.
Are SMMT insiders buying or selling?
In the last 12 months, SMMT insiders reported 4 open-market purchases worth $52.2M and no sales. The latest trade was on Jun 12, 2026. See every trade.
What is the short interest in SMMT?
As of Oct 30, 2026, 42.26M SMMT shares were sold short, 5.3% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 4.50M shares, buying them all back would take about 9.4 trading days (days to cover). See the history.
Which famous investors hold SMMT?
3 of the 50 well-known investors we track reported SMMT in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $64M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.